Navigation Links
FCC Approval of Finite Element Method for Biomedical Transmitters Puts ANSYS Software in the Spotlight
Date:3/3/2011

PITTSBURGH, March 3, 2011 /PRNewswire/ -- For specific electromagnetic applications in the healthcare industry, HFSS™ software from ANSYS (Nasdaq: ANSS) can now provide proof that a biomedical device transmitter design meets Federal Communications Commission (FCC) standards -- a ruling that will enable medical device developers to cut development time and costs while meeting safety standards.

(Logo: http://photos.prnewswire.com/prnh/20110127/MM38081LOGO)

The FCC ruled in February that the finite element method (FEM) is a valid technique to simulate a medical device that must communicate with other similar devices. As a result, organizations in the medical equipment sector can use HFSS -- industry-leading FEM electromagnetic field simulation -- to validate their transmitter designs.

Today’s sophisticated medical implants and other equipment often contain transmitters that communicate with other devices -- transferring physiological data to a doctor via wireless communication, for example, which can be used to monitor, diagnose or treat a patient’s condition. The new FCC ruling applies to transmitters that are placed inside, on, or in close proximity to the human body. Developers of such medical devices must ensure that their equipment meets radio frequency (RF) emission safety standards. Additionally, manufacturers must comply with specific absorption rate (SAR) regulations, a measure of how the body absorbs energy when exposed to an RF electromagnetic field. HFSS software -- which employs FEM simulation to verify both SAR and RF emissions -- can also reduce development time and costs while increasing reliability and design optimization.

“The HFSS finite element solution is extremely valuable for designing antenna systems for implantable devices,” said Mark Lanciault, principal electrical engineer, Cambridge Consultants, Inc. “Its use of an unstructured mesh is particularly well suited for modeling the complex curved surfaces within the human body, as seen in organs, tissues, and bones. Using HFSS allows us to optimize and verify performance of our implanted antenna designs in a representative environment. We will now be able to provide our customers accurate solutions specific to their device's location in the body.”

“The medical device market is rapidly innovating to meet consumer demands and satisfy regulatory safety requirements,” said Markus Kopp, product manager for electronics at ANSYS. “This FCC ruling allows researchers to innovate with HFSS, developing new approaches that they can get to market faster -- yet also maintain the FCC’s high standards of technical compliance. Beyond that, the ultimate beneficiary is the public, who will have quicker access to life-enhancing medical devices.”

ANSYS requested that the FCC grant a waiver to the Medical Device Radiocommunication Service rules to permit FEM environmental evaluation of medical implant or body-worn equipment. The ruling granting the waiver cited scientific literature stating that FEM is a sound engineering technique.

HFSS software, which incorporates industry-leading technology for 3-D full-wave electromagnetic field simulation, enables engineers to design, simulate and validate the behavior of complex high-performance RF, microwave and millimeter-wave devices in next-generation wireless devices, defense communication systems, biomedical devices, and consumer electronics.

About Cambridge Consultants, Inc. For over 50 years, Cambridge Consultants has led the way in innovative product development. We are the development partner of choice to many of the world’s leading blue chips as well as the virtual development team for ambitious start-up companies. We develop breakthrough products, create and license intellectual property, and provide business consultancy in technology-critical issues for clients worldwide, whether they are launching first-to-market products, entering new markets or expanding existing markets.

With a team of over 300 engineers, designers, scientists and consultants, in offices in Cambridge (UK) and Boston (USA), Cambridge Consultants offers solutions across a diverse range of industries including defence, medical technology, industrial and consumer products, transport, energy, cleantech and wireless communications.  

Cambridge Consultants is part of the Altran Group, the European leader in Innovation Consulting.

About ANSYS, Inc.ANSYS, Inc., founded in 1970, develops and globally markets engineering simulation software and technologies widely used by engineers, designers, researchers and students across a broad spectrum of industries and academia. The company focuses on the development of open and flexible solutions that enable users to analyze designs directly on the desktop, providing a common platform for fast, efficient and cost-conscious product development, from design concept to final-stage testing and validation. The company and its global network of channel partners provide sales, support and training for customers. Headquartered in Canonsburg, Pa., U.S.A., with more than 60 strategic sales locations throughout the world, ANSYS, Inc. and its subsidiaries employ more than 1,600 people and distribute ANSYS products through a network of channel partners in 40+ countries. Visit www.ansys.com for more information.

ANSYS, ANSYS Workbench, Ansoft, AUTODYN, CFX, FLUENT, and any and all ANSYS, Inc. brand, product, service and feature names, logos and slogans are registered trademarks or trademarks of ANSYS, Inc. or its subsidiaries in the United States or other countries. All other brand, product, service and feature names or trademarks are the property of their respective owners.

Technology: ANSS-TContactMedia

Fran Hensler724.514.2967fran.hensler@ansys.com Investors

Annette Arribas724.514.1782annette.arribas@ansys.com


'/>"/>

SOURCE ANSYS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
3. CryoCor Receives FDA Approval for Right Atrial Flutter
4. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
5. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
6. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
7. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
8. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
9. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
10. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
11. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):